Osf Heart Of Mary Medical Center
- Type
- Teaching hospital
- Where
- Urbana, IL
- Medicare CCN
- 140113
- Received
- $484,699 in 88 records, 2021 ($38,543 general, $446,155 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 12 | $38,543 |
| 2021 | Research payment | 76 | $446,155 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Janssen Research & Development, LLC | 16 | $254,721 | 2021 |
| Davol Inc. | 1 | $60,486 | 2021 |
| ENDOTRONIX, INC. | 1 | $52,808 | 2021 |
| Vifor (International) Ltd. | 39 | $26,573 | 2021 |
| Ethicon Inc. | 11 | $23,022 | 2021 |
| Medical Device Business Services, Inc. | 5 | $20,795 | 2021 |
| Chiesi USA, Inc. | 1 | $9,500 | 2021 |
| Ethicon US, LLC | 1 | $9,125 | 2021 |
| GE HEALTHCARE | 2 | $8,930 | 2021 |
| Roche Products Limited | 3 | $8,129 | 2021 |
| Biogen, Inc. | 3 | $4,435 | 2021 |
| KLS-Martin L.P. | 1 | $4,313 | 2021 |
| Abbott Laboratories | 3 | $1,610 | 2021 |
| Insulet Corporation | 1 | $250 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 76 | $446,155 |
| Space rental or facility fees (teaching hospital only) | 6 | $25,108 |
| Education | 1 | $9,125 |
| Debt forgiveness | 4 | $4,060 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $250 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Ethicon US, LLC | $9,125 | Education | In-kind items and services | SmartAblateTM System RF Generator Device, Generators | 2021 | |
| 2021-12-27 | Ethicon Inc. | $26 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-12-15 | Vifor (International) Ltd. | $1,000 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-12-15 | Vifor (International) Ltd. | $500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-12-15 | Vifor (International) Ltd. | $400 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-12-14 | Biogen, Inc. | $1,400 | Research payment | Cash or cash equivalent | TECFIDERA Drug, NEUROLOGY | Dimethyl Fumarate (DMF) Observational Study | 2021 |
| 2021-11-29 | Ethicon Inc. | $2,419 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-11-22 | Ethicon Inc. | $26 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-11-19 | Ethicon Inc. | $800 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-11-02 | Biogen, Inc. | $1,500 | Research payment | Cash or cash equivalent | TECFIDERA Drug, NEUROLOGY | Dimethyl Fumarate (DMF) Observational Study | 2021 |
| 2021-11-02 | Abbott Laboratories | $1,310 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-10-27 | Vifor (International) Ltd. | $750 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-10-27 | Abbott Laboratories | $100 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-10-27 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-10-25 | Chiesi USA, Inc. | $9,500 | Research payment | Cash or cash equivalent | CUROSURF Drug, NEONATOLOGY | 2021 | |
| 2021-10-19 | Abbott Laboratories | $200 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-10-19 | Ethicon Inc. | $166 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-10-12 | Roche Products Limited | $250 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2021 |
| 2021-10-05 | Roche Products Limited | $5,476 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2021 |
| 2021-09-15 | Vifor (International) Ltd. | $1,577 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-09-15 | Vifor (International) Ltd. | $1,027 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-09-13 | Janssen Research & Development, LLC | $6,436 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-09-09 | GE HEALTHCARE | $6,480 | Research payment | In-kind items and services | GE Ultrasound System Performance Evaluation R3 OSF Saint Francis Medical Center | 2021 | |
| 2021-09-08 | Vifor (International) Ltd. | $750 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-09-08 | Vifor (International) Ltd. | $750 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-09-08 | Vifor (International) Ltd. | $500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-09-08 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-08-13 | Ethicon Inc. | $1,538 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-08-11 | KLS-Martin L.P. | $4,313 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-08-09 | Ethicon Inc. | $951 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-07-29 | Janssen Research & Development, LLC | $670 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-07-19 | Ethicon Inc. | $2,948 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-07-12 | Ethicon Inc. | $11,200 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-06-28 | Janssen Research & Development, LLC | $7,380 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-28 | Insulet Corporation | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2021 | |
| 2021-06-25 | Janssen Research & Development, LLC | $29,379 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-25 | Janssen Research & Development, LLC | $6,042 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-25 | Janssen Research & Development, LLC | $1,585 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-25 | Janssen Research & Development, LLC | $670 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-21 | Janssen Research & Development, LLC | $10,947 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-06-21 | Ethicon Inc. | $529 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-06-07 | Janssen Research & Development, LLC | $335 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-05-24 | Ethicon Inc. | $2,419 | Research payment | Cash or cash equivalent | Research to further inform thinking about the role of LINX for Reflux Disease | 2021 | |
| 2021-05-12 | Vifor (International) Ltd. | $784 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-05-12 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-05-12 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-05-03 | Medical Device Business Services, Inc. | $5,795 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-04-21 | Vifor (International) Ltd. | $749 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-19 | Janssen Research & Development, LLC | $38,528 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-04-15 | Roche Products Limited | $2,403 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2021 |
| 2021-04-08 | Medical Device Business Services, Inc. | $3,320 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-04-07 | Vifor (International) Ltd. | $1,000 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $784 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $273 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-07 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-04-01 | ENDOTRONIX, INC. | $52,808 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2021 |
| 2021-04-01 | Biogen, Inc. | $1,535 | Research payment | Cash or cash equivalent | PLEGRIDY Biological, NEUROLOGY | Plegridy Observational Program | 2021 |
| 2021-03-24 | Vifor (International) Ltd. | $1,004 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-24 | Vifor (International) Ltd. | $1,004 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-24 | Vifor (International) Ltd. | $878 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-18 | Janssen Research & Development, LLC | $2,010 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-03-18 | Janssen Research & Development, LLC | $176 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-03-03 | Vifor (International) Ltd. | $1,466 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $1,466 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $750 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-03 | Vifor (International) Ltd. | $35 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-03-01 | Janssen Research & Development, LLC | $39,955 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-02-24 | Vifor (International) Ltd. | $3,564 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-02-24 | Vifor (International) Ltd. | $1,378 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-02-24 | Vifor (International) Ltd. | $1,378 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-02-24 | Vifor (International) Ltd. | $1,378 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2021 |
| 2021-02-15 | Janssen Research & Development, LLC | $44,942 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-02-15 | Janssen Research & Development, LLC | $43,804 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-02-15 | Janssen Research & Development, LLC | $21,861 | Research payment | Cash or cash equivalent | Phase 2 Randomized Double blind Placebo controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed C | 2021 | |
| 2021-02-15 | Medical Device Business Services, Inc. | $2,195 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-02-03 | GE HEALTHCARE | $2,450 | Debt forgiveness | Cash or cash equivalent | 2021 | ||
| 2021-01-28 | Medical Device Business Services, Inc. | $4,840 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-01-19 | Medical Device Business Services, Inc. | $4,645 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-01-04 | Davol Inc. | $60,486 | Research payment | Cash or cash equivalent | DVL-HE-018 | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Urbana, IL | County Champaign County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 39,341 | 208,741 | 12,694,798 |
| Population, 2020 census P1 | 38,336 | 205,865 | 12,812,508 |
| Median age B01002 | 26.1 | 30.7 | 39.0 |
| Under 18 B01001 | 13.2% | 19.1% | 21.8% |
| 65 and over B01001 | 11.5% | 13.9% | 17.0% |
| Households B11001 | 16,856 | 85,472 | 5,036,449 |
| Foreign born B05002 | 21.2% | 14.2% | 14.7% |
| Median household income B19013 | $45,346 | $63,683 | $83,390 |
| Median family income B19113 | $86,209 | $100,396 | $106,018 |
| Per capita income B19301 | $32,592 | $38,439 | $46,406 |
| Poverty rate B17001 | 28.0% | 19.1% | 11.8% |
| Unemployment rate B23025 | 4.7% | 4.3% | 5.8% |
| Civilian labor force B23025 | 20,316 | 104,876 | 6,652,134 |
| Mean commute (minutes) B08013 | 14.2 | 16.9 | 27.8 |
| Bachelor's degree or higher B15003 | 56.7% | 46.2% | 37.8% |
| Housing units B25001 | 19,228 | 95,115 | 5,457,452 |
| Owner-occupied B25003 | 37.3% | 54.0% | 67.1% |
| Renters B25003 | 62.7% | 46.0% | 32.9% |
| Median home value B25077 | $184,900 | $211,500 | $263,300 |
| Median gross rent B25064 | $972 | $1,051 | $1,274 |
| White, not Hispanic B03002 | 52.9% | 62.4% | 58.1% |
| Black B03002 | 18.7% | 13.4% | 13.3% |
| Hispanic or Latino B03002 | 10.1% | 8.3% | 18.8% |
| Asian B03002 | 14.2% | 11.4% | 5.9% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.
Comments